Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer

In 161 patients with NMIBC who underwent repeat TURBT, tissue-naive urinary tumor DNA was collected 2 to 6 weeks after the first resection and before the second. Residual tumor was found in 57 patients (35.4%). Adding utDNA raised the AUC for residual tumor from about 0.54 to about 0.89 across guideline-based indication sets, and improved recurrence-risk discrimination beyond EAU and EORTC models (and, in the same direction, CUETO).

JCO Precision Oncology. November 4, 2026. PMID 42981539. doi 10.1200/PO-26-00676.PubMed 42981539